Integrin CD11b activation drives anti-tumor innate immunity

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• Myeloid cells are crucial in tissue repair and disease, with their recruitment influenced by integrins like CD11b.
• Integrin CD11b is known to regulate cell adhesion and migration, particularly in myeloid cells.

Purpose of the Study:

• To investigate the role of integrin CD11b in myeloid cell recruitment and function within the tumor microenvironment.
• To explore the potential of targeting CD11b for cancer immunotherapy.

Main Methods:

• Utilized animal models of murine and human cancer.
• Investigated the effects of CD11b activation and inhibition on myeloid cell polarization.
• Analyzed the expression of microRNA Let7a and cMyc in response to CD11b modulation.
• Administered Leukadherin 1 (LA1), a small molecule CD11b agonist.

Main Results:

• Integrin CD11b does not regulate myeloid cell recruitment to tumors but controls their polarization and tumor growth.
• CD11b activation stimulates pro-inflammatory macrophage polarization via Let7a microRNA.
• CD11b inhibition leads to immune-suppressive macrophage polarization, vascular maturation, and accelerated tumor growth.
• LA1 treatment promotes pro-inflammatory macrophage polarization and suppresses tumor growth in cancer models.

Conclusions:

• Integrin CD11b acts as a negative regulator of immune suppression in the tumor microenvironment.
• Targeting CD11b, for example with LA1, represents a promising strategy for cancer immune therapy.